Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1164/rccm.201308-1543PP http://scihub22266oqcxt.onion/10.1164/rccm.201308-1543PP 24401129!ä!24401129 Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=24401129&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Am+J+Respir+Crit+Care+Med 2014 ; 189 (4): 394-400 Nephropedia Template TP {{tp|p=24401129|t=2014. Novel and emerging therapies for pulmonary hypertension |pdf=|usr=}}{{24401129}} gab.com Text Novel and emerging therapies for pulmonary hypertension JO: Am J Respir Crit Care Med http://www.kidney.de/pget.php?&tw=1&pmid=24401129 #FOAvip The development of therapeutic concepts in pulmonary hypertension (PH) is intimately linked with the unraveling of pathogenetic sequelae. This perspective highlights advances in our understanding of the regulation of vasomotion and vascular remodeling that have led to "reverse-remodeling" and regenerative strategies as novel treatment concepts. Progress has been made in understanding redox-dependent signaling; inflammatory sequelae; and transcription factor, ion channel, and metabolic abnormalities, as well as growth factor-dependent hyperproliferation that underlies PH. We are, however, far from understanding the molecular pathways that differentially drive the various vascular phenotypes (intimal thickening, media hypertrophy, adventitial thickening, plexiform lesions, vascular pruning) in this disease. Antiproliferative strategies, transcription factor-based therapies, inflammation/immune cell-focused approaches, and epigenetic modulation-based therapies are all novel treatment concepts for PH. The proangiogenic potential of genetically engineered mesenchymal stem cells and endothelial progenitor cells has been explored as a regenerative strategy. The progress that has been made in identifying important cellular and molecular mechanisms and applying this knowledge to novel therapies is largely restricted to group 1 PH. However, understanding the molecular sequelae underlying PH in groups 2 through 5 PH is also urgently needed. Twit Text FOAVip Novel and emerging therapies for pulmonary hypertension ????Am J Respir Crit Care Med http://www.kidney.de/pget.php?&tw=1&pmid=24401129 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=24401129 #FOAvip English Wikipedia <ref>{{Cite pmid|24401129}}</ref> Novel and emerging therapies for pulmonary hypertension #MMPMID24401129 Pullamsetti SS; Schermuly R; Ghofrani A; Weissmann N; Grimminger F; Seeger W Am J Respir Crit Care Med 2014[Feb]; 189 (4): 394-400 PMID24401129show ga The development of therapeutic concepts in pulmonary hypertension (PH) is intimately linked with the unraveling of pathogenetic sequelae. This perspective highlights advances in our understanding of the regulation of vasomotion and vascular remodeling that have led to "reverse-remodeling" and regenerative strategies as novel treatment concepts. Progress has been made in understanding redox-dependent signaling; inflammatory sequelae; and transcription factor, ion channel, and metabolic abnormalities, as well as growth factor-dependent hyperproliferation that underlies PH. We are, however, far from understanding the molecular pathways that differentially drive the various vascular phenotypes (intimal thickening, media hypertrophy, adventitial thickening, plexiform lesions, vascular pruning) in this disease. Antiproliferative strategies, transcription factor-based therapies, inflammation/immune cell-focused approaches, and epigenetic modulation-based therapies are all novel treatment concepts for PH. The proangiogenic potential of genetically engineered mesenchymal stem cells and endothelial progenitor cells has been explored as a regenerative strategy. The progress that has been made in identifying important cellular and molecular mechanisms and applying this knowledge to novel therapies is largely restricted to group 1 PH. However, understanding the molecular sequelae underlying PH in groups 2 through 5 PH is also urgently needed. |Angiogenesis Inhibitors/therapeutic use[MESH] |Antihypertensive Agents/*therapeutic use[MESH] |Epigenesis, Genetic[MESH] |Familial Primary Pulmonary Hypertension[MESH] |Histone Deacetylase Inhibitors/therapeutic use[MESH] |Humans[MESH] |Hypertension, Pulmonary/*drug therapy/genetics/immunology/physiopathology[MESH] |Protein Kinase Inhibitors/*therapeutic use[MESH] |Pulmonary Artery/physiopathology[MESH] |Pyrazoles/therapeutic use[MESH] |Pyrimidines/therapeutic use[MESH] |Sulfonamides/therapeutic use[MESH] |Vasodilation[MESH]Novel and emerging therapies for pulmonary hypertension (epmc).pdf DeepDyve Pubget Overpricing